Impact of

BACKGROUND

Gut microbiota composition can influence cancer immunotherapy response. Recent evidence suggests

METHODS

This single-center, retrospective study included all ICI-treated individuals with metastatic gastric cancer and documented

RESULTS

Of 215 included patients, 49 had documented history of

CONCLUSIONS

In this largest study of its kind,

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: SBM has received research funding from Guardant Health, and consulted for Basilea, Bicara, Daiichi-Sankyo, Elevation Oncology, Purple Oncology, Amgen, Novartis, and Natera. MS serves on the advisory board for Boston Scientific, Mirai Medical, and Novo Nordisk. YJ has stock or ownership interest in RGENIX; has a consulting or advisory role with AstraZeneca, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Imugene, Merck Serono, Merck, Michael J Hennessy Associates, Paradigm Medical Communications, Pfizer, RGENIX, Seagen and Zymeworks; and has received research funding from Bayer, Bristol Myers Squibb, Cycle for Survival, Department of Defense, Eli Lilly, Fred’s Team, Genentech/Roche, Merck, NCI and RGENIX. DF has received consulting fees from AzurRx, Equillium, Kaleido Biosciences, Mallinckrodt Pharmaceuticals, and OnQuality Pharmaceuticals. All other authors have no conflicts of interest to disclose.